KYMERA THERAPEUTICS, INC. Investing Cash Flow
KYMERA THERAPEUTICS, INC. (KYMR) reported Investing Cash Flow of -$122.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $20.05M, a 66.60% decline year-over-year.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$142.84M, a 393.82% decline year-over-year.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$394.40M, a 675.19% decline year-over-year.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$235.30M.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$521.06M.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$404.08M, a 388.86% decline from fiscal 2023.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2023 was $139.89M, a 581.74% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2022 was $20.52M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$122.80M 10-Q · filed 2026-08-05 | -$517.19M derived: sum of 3 quarters · filed 2026-08-05 | -$752.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$142.84M 10-Q · filed 2026-04-30 | -$537.24M derived: sum of 2 quarters · filed 2026-04-30 | -$772.54M derived: sum of 3 quarters · filed 2026-04-30 | -$712.52M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$394.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$629.70M derived: sum of 2 quarters · filed 2026-02-26 | -$569.68M derived: sum of 3 quarters · filed 2026-08-05 | -$521.06M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$235.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$175.28M derived: sum of 2 quarters · filed 2026-08-05 | -$126.66M 10-Q · filed 2025-11-04 | -$58.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $60.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $108.64M 10-Q · filed 2026-08-05 | $177.20M derived: sum of 3 quarters · filed 2026-08-05 | $19.52M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $48.62M 10-Q · filed 2026-04-30 | $117.18M derived: sum of 2 quarters · filed 2026-04-30 | -$40.50M derived: sum of 3 quarters · filed 2026-04-30 | -$24.86M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $68.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$89.11M derived: sum of 2 quarters · filed 2026-02-26 | -$73.47M derived: sum of 3 quarters · filed 2026-02-26 | -$404.08M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$157.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$142.04M derived: sum of 2 quarters · filed 2025-11-04 | -$472.64M 10-Q · filed 2025-11-04 | -$453.69M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $15.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$314.96M 10-Q · filed 2025-08-11 | -$296.01M derived: sum of 3 quarters · filed 2026-02-26 | -$235.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$330.61M 10-Q · filed 2025-05-09 | -$311.65M derived: sum of 2 quarters · filed 2026-02-26 | -$251.14M derived: sum of 3 quarters · filed 2026-02-26 | -$215.31M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $18.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $79.46M derived: sum of 2 quarters · filed 2026-02-26 | $115.30M derived: sum of 3 quarters · filed 2026-02-26 | $139.89M 10-K · filed 2026-02-26 |
| 2023-09-30 | $60.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $96.35M derived: sum of 2 quarters · filed 2024-10-31 | $120.93M 10-Q · filed 2024-10-31 | $71.27M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $35.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $60.42M 10-Q · filed 2024-08-07 | $10.76M derived: sum of 3 quarters · filed 2025-02-27 | -$26.72M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $24.58M 10-Q · filed 2024-05-02 | -$25.08M derived: sum of 2 quarters · filed 2025-02-27 | -$62.56M derived: sum of 3 quarters · filed 2025-02-27 | $19.24M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$49.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$87.15M derived: sum of 2 quarters · filed 2025-02-27 | -$5.34M derived: sum of 3 quarters · filed 2025-02-27 | $20.52M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$37.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $44.32M derived: sum of 2 quarters · filed 2023-11-02 | $70.19M 10-Q · filed 2023-11-02 | $2.17M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $81.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $107.67M 10-Q · filed 2023-08-03 | $39.65M derived: sum of 3 quarters · filed 2024-02-22 | -$97.22M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $25.86M 10-Q · filed 2023-05-04 | -$42.16M derived: sum of 2 quarters · filed 2024-02-22 | -$179.02M derived: sum of 3 quarters · filed 2024-02-22 | -$118.30M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$68.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$204.88M derived: sum of 2 quarters · filed 2024-02-22 | -$144.16M derived: sum of 3 quarters · filed 2024-02-22 | -$99.83M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$136.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$76.14M derived: sum of 2 quarters · filed 2022-11-03 | -$31.82M 10-Q · filed 2022-11-03 | -$35.81M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $60.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $105.05M 10-Q · filed 2022-08-09 | $101.06M derived: sum of 3 quarters · filed 2023-02-23 | -$233.26M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $44.32M 10-Q · filed 2022-05-03 | $40.33M derived: sum of 2 quarters · filed 2023-02-23 | -$293.99M derived: sum of 3 quarters · filed 2023-02-23 | -$340.86M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$3.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$338.31M derived: sum of 2 quarters · filed 2023-02-23 | -$385.19M derived: sum of 3 quarters · filed 2023-02-23 | -$422.59M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$334.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$381.19M derived: sum of 2 quarters · filed 2021-11-10 | -$418.60M 10-Q · filed 2021-11-10 | -$356.64M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$46.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$84.28M 10-Q · filed 2021-08-06 | -$22.32M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | -$37.40M 10-Q · filed 2021-05-06 | $24.56M derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $61.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$16.49M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | -$78.44M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |